Marker Therapeutics, Inc.

+1 (713) 400-6400

3200 Southwest Fwy #2240 Phoenix Tower
Houston, TX 77027

© 2020 Marker Therapeutics, Inc.

A major leap forward in cell therapy

Learn More

Marker Therapeutics Reports Update from TACTOPS Trial with MultiTAA-Specific T Cell Therapy in Pancreatic Cancer at ASCO20

View Press Release Here

View Poster Here

The Company

We are a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. We developed our lead product candidates from our MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Recognition

Marker Therapeutics, Inc. Congratulates Dr. James P. Allison for Receiving the 2018 Nobel Prize in Medicine or Physiology

Marker Therapeutics, Inc. Congratulates Dr. Padmanee Sharma for Receiving the William B. Coley Award for Distinguished Research in Tumor Immunology

At the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR, Baylor College of Medicine Presented Data on Several Baylor Clinical Trials Employing Technology Exclusively Licensed to Marker

Marker Therapeutics Announces New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates

Marker Therapeutics, Inc., today announced that it has executed a lease agreement to establish a cGMP manufacturing facility in Houston, TX, in an area near the George Bush Intercontinental Airport. The facility will allow production according to U.S. Food and Drug Administration (FDA) guidelines and is designed to be scalable using modular processes. The facility is expected to be completed by year-end and operational in 2021.

Read more

Marker Therapeutics Receives USAN Approval for “zelenoleucel” as Nonproprietary Name for MT-401, Multi-Tumor-Associated Antigen Targeted T Cell Product for Acute Myeloid Leukemia

Marker Therapeutics, Inc. announced today that the United States Adopted Name (USAN) Council has approved “zelenoleucel” as the nonproprietary (generic) name for MT-401, a multi-tumor-associated antigen (MultiTAA)-specific T cell product candidate for the treatment of patients with acute myeloid leukemia (AML) following allogeneic stem cell transplant in both adjuvant and active disease settings.

Read more

Clinical Studies

Marker has multiple clinical studies ongoing and planned for its multi-antigen T cell therapies. Target indications include acute myelogenous leukemia (AML), non-Hodgkin lymphoma (NHL), multiple myeloma (MM) and breast cancer.

Technology

Marker’s unique cell therapy platform is the first to successfully target multiple tumor-associated antigens simultaneously, without the need for genetic modification of patients’ T cells. The result is a remarkably robust and durable anti-tumor immune response and a manufacturing process that is simpler and less costly than today’s TCR and CAR-T therapy.

Pipeline

Marker has a deep pipeline of clinical-stage programs that leverage the company’s unique multi-TAA cell therapy platform, addressing multiple hematologic malignancies and solid tumors. The company is also advancing its novel peptide vaccine in breast and ovarian cancer.

Management Team

Marker is led by an executive management team specialized in cancer immunotherapy, bringing together extensive corporate, clinical, translational and medical experience. With its world-class scientific advisors, Marker is well positioned to advance its science-based approach to transforming the cell therapy landscape.

Sign up for email alerts

Get Marker News Delivered To Your Inbox

Sign Up Today

© 2020 Marker Therapeutics, Inc.